Journal
TRANSPLANT INTERNATIONAL
Volume 26, Issue 6, Pages 576-589Publisher
WILEY
DOI: 10.1111/tri.12081
Keywords
cellular therapy; clinical trials; immune regulation; regulatory T cell; tolerance; transplantation
Categories
Funding
- Wellcome Trust
- Medical Research Council UK
- British Heart Foundation
- Roche Organ Transplant Research Foundation
- Restore
- Burn and Wound Research Trust
- European Union
- British Heart Foundation [FS/12/72/29754] Funding Source: researchfish
- Medical Research Council [G0800842] Funding Source: researchfish
- National Institute for Health Research [ACF-2013-18-020] Funding Source: researchfish
- MRC [G0800842] Funding Source: UKRI
Ask authors/readers for more resources
Since the first solid organ transplant between the Herrick twins in 1954, transplantation immunology has sought to move away from harmful immunosuppressive regimens towards tolerogenic strategies that promote long-term graft survival. This has required a concerted multinational effort with scientists and clinicians working towards a common goal. Reports of immunosuppression-free kidney and liver allograft recipients have provided the proof-of-principle, but intentional generation of tolerance in clinical transplantation is still only achieved infrequently. Recently, there have been an increasing number of encouraging developments in the field in both experimental and clinical studies. In this article, we review the latest advances in tolerance research and consider possible future barriers and solutions in achieving reliable graft acceptance in the long term.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available